Ascentage Pharma: Trustee Buys 110,000 Shares for 2022 RSU Scheme at HK$33.37 Each

Bulletin Express

06/11

Ascentage Pharma Group International announced that the trustee of its 2022 Restricted Share Unit (RSU) Scheme purchased 110,000 existing shares on-market on 11 June 2026 to satisfy upcoming vesting of RSUs.

The transaction amounted to HK$3.67 million, implying an average consideration of HK$33.37 per share. The acquired shares represent approximately 0.03% of Ascentage Pharma’s total issued share capital.

Following this purchase, the trustee’s aggregate on-market holdings for the 2022 RSU Scheme increased to 2.62 million shares. Shares held by the trustee are subject to the scheme’s rules, and the trustee is not entitled to exercise voting rights attached to these shares.

No additional RSU awards have been granted beyond the initial allocation on 23 June 2022 and subsequent grants disclosed on 4 May 2023, 2 September 2024, 27 June 2025, 26 November 2025 and 20 April 2026.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1121548855"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1121548855\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1121548855?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-11 21:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121548855","market":"us","top_or_hot":-1,"title":"Ascentage Pharma: Trustee Buys 110,000 Shares for 2022 RSU Scheme at HK$33.37 Each","media":"Bulletin Express","content":"<p>Ascentage Pharma Group International announced that the trustee of its 2022 Restricted Share Unit (RSU) Scheme purchased 110,000 existing shares on-market on 11 June 2026 to satisfy upcoming vesting of RSUs.</p>\n<p>The transaction amounted to HK$3.67 million, implying an average consideration of HK$33.37 per share. The acquired shares represent approximately 0.03% of Ascentage Pharma’s total issued share capital.</p>\n<p>Following this purchase, the trustee’s aggregate on-market holdings for the 2022 RSU Scheme increased to 2.62 million shares. Shares held by the trustee are subject to the scheme’s rules, and the trustee is not entitled to exercise voting rights attached to these shares.</p>\n<p>No additional RSU awards have been granted beyond the initial allocation on 23 June 2022 and subsequent grants disclosed on 4 May 2023, 2 September 2024, 27 June 2025, 26 November 2025 and 20 April 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ascentage Pharma: Trustee Buys 110,000 Shares for 2022 RSU Scheme at HK$33.37 Each</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAscentage Pharma: Trustee Buys 110,000 Shares for 2022 RSU Scheme at HK$33.37 Each\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-11 21:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ascentage Pharma Group International announced that the trustee of its 2022 Restricted Share Unit (RSU) Scheme purchased 110,000 existing shares on-market on 11 June 2026 to satisfy upcoming vesting of RSUs.</p>\n<p>The transaction amounted to HK$3.67 million, implying an average consideration of HK$33.37 per share. The acquired shares represent approximately 0.03% of Ascentage Pharma’s total issued share capital.</p>\n<p>Following this purchase, the trustee’s aggregate on-market holdings for the 2022 RSU Scheme increased to 2.62 million shares. Shares held by the trustee are subject to the scheme’s rules, and the trustee is not entitled to exercise voting rights attached to these shares.</p>\n<p>No additional RSU awards have been granted beyond the initial allocation on 23 June 2022 and subsequent grants disclosed on 4 May 2023, 2 September 2024, 27 June 2025, 26 November 2025 and 20 April 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06855","symbol_name":"亚盛医药","start_time":0,"source_url":"","article_id":"1121548855","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121548855","pubTimestamp":1781185366,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Ascentage Pharma Group International announced that the trustee of its 2022 Restricted Share Unit (RSU) Scheme purchased 110,000 existing shares on-market on 11 June 2026 to satisfy upcoming vesting...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06855":"亚盛医药"},"translate_title":"亚盛医药：受讬人按每股33.37港元购买110,000股2022年受限制股份单位计划股份","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06855":1},"content_text":"Ascentage Pharma Group International announced that the trustee of its 2022 Restricted Share Unit (RSU) Scheme purchased 110,000 existing shares on-market on 11 June 2026 to satisfy upcoming vesting of RSUs.\nThe transaction amounted to HK$3.67 million, implying an average consideration of HK$33.37 per share. The acquired shares represent approximately 0.03% of Ascentage Pharma’s total issued share capital.\nFollowing this purchase, the trustee’s aggregate on-market holdings for the 2022 RSU Scheme increased to 2.62 million shares. Shares held by the trustee are subject to the scheme’s rules, and the trustee is not entitled to exercise voting rights attached to these shares.\nNo additional RSU awards have been granted beyond the initial allocation on 23 June 2022 and subsequent grants disclosed on 4 May 2023, 2 September 2024, 27 June 2025, 26 November 2025 and 20 April 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}